Overview

Study Evaluating Single Ascending Doses Of ILS-920

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human study of ILS-920. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ILS-920 after administration of ascending single intravenous (IV) doses to healthy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer